Therapeutic antibody development company Patrys (ASX:PAB) has announced new pre-clinical data for its lead asset, PAT-DX1, from a study conducted by Professor Terrence Johns of the Telethon Kids Cancer Centre.
Partrys' candidate in combination improves survival in brain cancer model
August 11, 2022 Australian Biotech
Latest Video
New Stories
-
The 'Dispatched' Podcast Week in Review - Series 5. Ep.34
October 2, 2026 - - Podcast -
Under the TGA's new rules, the safest story is one without the patient experience
October 2, 2026 - - Latest News -
US announces formal plan that benchmarks pricing against Australia and 18 other countries
October 1, 2026 - -
Sandoz leads pharma's best workplaces as Rare Cancers Australia makes healthcare list
October 1, 2026 - - Latest News -
Eczema patients who don't respond to steroids get subsidised access to ointment
October 1, 2026 - - Latest News -
By the TGA's own test, the Health Minister's press releases are advertising
October 1, 2026 - - Latest News -
The regulator that deleted the truth from its answers now wants to police the media
October 1, 2026 - - Latest News
